Key result
12-month acarbose use is linked to lower arterial stiffness and vascular remodeling markers in T2D.
Why the study?
Does acarbose improve arterial stiffness in patients with type 2 diabetes mellitus?
Observational (n=22)
Does acarbose improve arterial stiffness in patients with type 2 diabetes mellitus?
Acarbose treatment for 12 months significantly improves arterial stiffness and reduces vascular remodeling markers in patients with type 2 diabetes mellitus.
Answers are grounded in this paper and cite their sources.
May support vascular benefits of acarbose in T2DM; hypothesis-generating and should not change practice without RCTs.
UNLABELLED: Aims/Introduction: Although the improvement of postprandial hyperglycemia by an alpha-glucosidase inhibitor (α-GI) has been associated with a risk reduction of cardiovascular events, the relationship between postprandial hyperglycemia and arterial stiffness has not been well understood. We therefore examined whether ameliorating the postprandial state by α-GI leads to an improvement in arterial stiffness. MATERIALS AND METHODS: A total of 22 patients with type 2 diabetes mellitus were treated with acarbose. Cardio-ankle vascular index (CAVI) as the arterial stiffness was measured by using a VaSera CAVI instrument before and 12 months after acarbose treatment. Serum high-sensitivity C-reactive protein (hs-CRP), pentraxin-3 (PTX3) and matrix metalloproteinase (MMP) -2, -9 were measured at the same time points. Furthermore, circulating peripheral blood mononuclear cells were examined for the frequencies of CD14 positive cells expressing membrane type-1 MMP (MT1-MMP) at the single cell level using flow cytometry. RESULTS: After acarbose treatment, postprandial glucose and glycosylated hemoglobin (HbA1c) were significantly decreased. Serum levels of hs-CRP, PTX3, MMP-2 and MMP-9 were significantly decreased. CAVI showed a significant reduction, although the changes were not significant in blood pressure and heart rate. MT1-MMP expression was significantly decreased by acarbose treatment. In multivariate analysis, improvement of blood glucose, decrease of PTX3 levels and MT1-MMP expression were independent predictors of beneficial change in CAVI. CONCLUSIONS: The present study showed that the beneficial effects of acarbose on arterial stiffness are mediated by an improvement of postprandial hyperglycemia and vascular remodeling markers. In conclusion, acarbose treatment might reduce the risk of cardiovascular diseases by altering the arterial stiffness in postprandial hyperglycemic status. (J Diabetes Invest, doi:10.1111/j.2040-1124.2010.00079.x, 2010).
No takes yet. Share an insight, caveat, or question.
Uzui et al. (2010) conducted an observational in type 2 diabetes mellitus (n=22). Acarbose was evaluated on Cardio-ankle vascular index (CAVI). Acarbose treatment for 12 months significantly reduced arterial stiffness (measured by CAVI) and vascular remodeling markers in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: